Amplia Therapeutics Ltd logo

Amplia Therapeutics Ltd

ASX:ATX (Australia)  
A$ 0.08 (0%) Feb 29
At Loss
P/B:
0.98
Market Cap:
A$ 14.55M ($ 9.46M)
Enterprise V:
A$ 11.13M ($ 7.24M)
Volume:
-
Avg Vol (2M):
51.88K
Also Trade In:
Volume:
-
At Loss
Avg Vol (2M):
51.88K

Business Description

Description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 2.53
Equity-to-Asset 0.84
Debt-to-Equity 0.15
Debt-to-EBITDA -0.52
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 35.54
9-Day RSI 39.63
14-Day RSI 41.79
6-1 Month Momentum % -9.09
12-1 Month Momentum % -5.88

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.43
Quick Ratio 3.43
Cash Ratio 2.06

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -38.8
Shareholder Yield % -0.37

Profitability Rank

Name Current Vs Industry Vs History
ROE % -26.96
ROA % -23.04
ROIC % -59.61
ROC (Joel Greenblatt) % -251.45
ROCE % -26.29

Financials

ASX:ATX's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Amplia Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.023
Beta 0.56
Volatility % 40.45
14-Day RSI 41.79
14-Day ATR (A$) 0.002198
20-Day SMA (A$) 0.07855
12-1 Month Momentum % -5.88
52-Week Range (A$) 0.062 - 0.115
Shares Outstanding (Mil) 194.01

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Amplia Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Amplia Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Amplia Therapeutics Ltd Frequently Asked Questions

What is Amplia Therapeutics Ltd(ASX:ATX)'s stock price today?
The current price of ASX:ATX is A$0.08. The 52 week high of ASX:ATX is A$0.12 and 52 week low is A$0.06.
When is next earnings date of Amplia Therapeutics Ltd(ASX:ATX)?
The next earnings date of Amplia Therapeutics Ltd(ASX:ATX) is .
Does Amplia Therapeutics Ltd(ASX:ATX) pay dividends? If so, how much?
Amplia Therapeutics Ltd(ASX:ATX) does not pay dividend.

Press Release

Subject Date
No Press Release